Shares in AstraZeneca jumped 6 percent on Wednesday after the drug maker won a key patent battle in the United States over Seroquel, its anti-psychotic drug and second-best seller. The decision by a U.S. court to award a summary judgment in AstraZeneca's favor avoids the need for a full trial and means that generic copies of the drug, which made $4 billion in sales last year, will not be launched in the near future.
July 02, 2008 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Shares in AstraZeneca PLC jumped 6 percent on Wednesday after the drug maker won a key patent battle in the United States over Seroquel, its anti-psychotic drug and second-best-seller.
The decision by a U.S. court to award a summary judgment in AstraZeneca’s favor avoids the need for a full trial and means that generic copies of the drug, which made $4 billion in sales last year, will not be launched in the near future.
Presented by BigVoodoo
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Lower Manhattan firm seeks a premises liability litigator (i.e., depositions, SJ motions, and/or trials) with at least 3-6 years of experien...
Evergreen Trading is a media investment firm headquartered in NYC. We help brands achieve their goals by leveraging their unwanted assets to...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
